



AnaptysBio

Leader in SHM for
Antibody Therapeutics

FOR IMMEDIATE RELEASE

March 1, 2010

**ANAPTYSBIO ADDS STRATEGIC COLLABORATION
WITH ANOTHER LEADING GLOBAL PHARMACEUTICAL COMPANY**

***Third Agreement Announced in Two Months for Somatic Hypermutation (SHM) Platform
to Generate Novel Antibody Therapeutics***

SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with an undisclosed leading global pharmaceutical company to generate novel antibody therapeutics to a specified disease target. This is the third collaboration with a leading pharmaceutical company announced by AnaptysBio during 2010.

Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) technology platform. The pharmaceutical company will receive worldwide rights to develop and commercialize antibodies generated by AnaptysBio. AnaptysBio receives an upfront sum and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.

“SHM is recognized as the key mechanism for the natural evolution and optimization of antibodies in the immune system,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “AnaptysBio has taken full advantage of this knowledge to create a powerful, next generation platform with distinct technical advantages for generating therapeutically useful antibodies.”

About AnaptysBio’s SHM-Platform™

AnaptysBio’s SHM-Platform™ is a mammalian cell-based system made possible by recent scientific advances in understanding how the body naturally creates potent antibodies to fight disease. Mammalian cell-based systems have long been desired for antibody discovery and maturation but until recently cell-based approaches have been restricted to the use of more primitive microbial-based display systems such as phage, bacteria or yeast. These systems often result in antibodies which require further maturation, usually accomplished by random mutagenesis which introduces non-human sequences into the antibody. AnaptysBio has overcome the limitations previously associated with mammalian cell systems by using SHM, the natural mechanism for human antibody maturation. AnaptysBio’s approach allows antibodies to be matured directly in their native context, but using a highly controllable system and without the constraints and limitations imposed by the body which can hinder the successful generation of useful antibodies. AnaptysBio’s approach results in mature human antibodies, co-selected for high affinity, solubility and high-level expression and greatly increases the probability of the antibody selected becoming a viable therapeutic agent.

Key features of AnaptysBio’s SHM-Platform™ include:



AnaptysBio

Leader in SHM for
Antibody Therapeutics

- Evolving, “natural” antibody sequence diversity
 - The SHM-Platform™ improves antibody properties by introducing a pattern of changes – the same as that seen in nature – through an iterative process of evolution and selection until the desired design goals have been achieved
- Integration of state-of-the-art technologies
 - The use of mammalian expression, secretion and cell-surface display, and high throughput selection using flow cytometry increases the probability of technical success and provides speed advantages
- Multiple applications
 - From *de novo* discovery and optimization of antibodies to serving as an ideal finishing step for transforming antibodies generated by other platforms into therapeutically useful product candidates.

About AnaptysBio

Founded in 2005, AnaptysBio, Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. The Company’s SHM-Platform™ utilizes the key components of SHM and other state-of-the-art techniques such as mammalian cell expression/display and flow cytometry to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. The company has established broad intellectual property around the use of SHM for therapeutic antibody applications, and is currently building a pipeline of novel therapeutic antibody product candidates. For more information on AnaptysBio and its SHM platform, visit www.anaptysbio.com.

Contacts:

Gable PR – 619-284-1714

Tom Gable

tom@gablepr.com

Cell: 619-251-3881